ACOX1-sEDD: Navigating Diagnosis and Therapy for a Rare Neurocutaneous Disorder

Recent pediatric reports have revolutionized our understanding of ACOX1-sEDD diagnosis and treatment. This ultrarare neurocutaneous disorder stems from gain-of-function variants in the ACOX1 gene. These genetic changes trigger excessive oxidative activity, which eventually causes multisystem injury in infants. Furthermore, the discovery of de novo ROBO1 variants suggests that additional genetic factors may modify how this disease expresses itself clinically.

Clinical Presentation and Multi-system Involvement

Infants with ACOX1-sEDD typically present early in life with distinct dermatologic features. Specifically, they develop a generalized erythematous desquamative greasy eruption within the first few weeks. Additionally, clinicians often observe sparse, dysplastic, ocher-colored scalp hair. Ocular involvement is also a significant concern. Patients frequently suffer from recurrent bilateral corneal epithelial defects. Consequently, early ophthalmic evaluation remains vital for preventing long-term vision loss.

The neurologic progression of the disorder is often severe. Most affected infants exhibit progressive hypotonia and failure to thrive. Moreover, seizures and diffuse symmetric leukoencephalopathy on brain MRI are common findings. Interestingly, metabolic testing might show elevated dicarboxylic acids even when very-long-chain fatty acids remain normal. Therefore, doctors should prioritize trio exome sequencing to confirm the diagnosis when these symptoms cluster together.

Metabolic Markers in ACOX1-sEDD Diagnosis and Treatment

Accurate identification relies on recognizing the unique metabolic profile of the condition. While classical peroxisomal biomarkers often stay within normal limits, elevated medium- and long-chain acylcarnitines provide important clues. Because of the excessive oxidative stress caused by the ACOX1 p.Asn237Ser variant, targeted antioxidant therapies are necessary. These treatments aim to neutralize the reactive oxygen species that damage Schwann cells and neurons.

Current Management Strategies

Therapeutic success largely depends on early intervention. For cutaneous lesions, topical 10% N-acetylcysteine (NAC) and emollients have shown excellent results. Furthermore, oral NAC and adjunctive antioxidant vitamin therapy help manage systemic oxidative damage. For ocular issues, specialists recommend vitamin A ointment and autologous serum eyedrops. These combined efforts significantly improve the quality of life for these young patients.

Frequently Asked Questions

What is the primary cause of ACOX1-sEDD?

ACOX1-sEDD is primarily caused by gain-of-function variants in the ACOX1 gene, which lead to increased oxidative stress and subsequent damage to the skin, eyes, and nervous system.

How does ACOX1-sEDD differ from classical peroxisomal disorders?

Unlike many peroxisomal disorders, ACOX1-sEDD may present with normal very-long-chain fatty acids (VLCFAs) but shows elevated dicarboxylic acids and specific gain-of-function genetic mutations via exome sequencing.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Molina-Espinosa J et al. ACOX1 Gain-of-Function and De Novo ROBO1 Variant in ACOX1-sEDD. Pediatr Dermatol. 2026 Jun 22. doi: 10.1111/pde.70299. PMID: 42331342.

Chung HL et al. Loss or gain of function mutations in ACOX1 cause axonal loss via different mechanisms. Neuron. 2020;106(4):589-606.e6.

Filippi C et al. ACOX1 gain-of-function variation in a 10-years-old patient responsive to immunomodulating therapy. Am J Med Genet A. 2024;194(9):e63681.